Cargando…

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

The recepteur d’origine nantais (RON) receptor tyrosine kinase, belonging to the mesenchymal-to-epithelial transition proto-oncogene family, has been implicated in the pathogenesis of cancers derived from the colon, lung, breast, and pancreas. These findings lay the foundation for targeting RON for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Hang-Ping, Suthe, Sreedhar Reddy, Tong, Xiang-Min, Wang, Ming-Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222236/ https://www.ncbi.nlm.nih.gov/pubmed/32426050 http://dx.doi.org/10.1177/1758835920920069

Ejemplares similares

Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019)

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy
por: Tong, Xiang-Min, et al.
Publicado: (2019)

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160
por: Lu, Yi, et al.
Publicado: (2008)

Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain
por: Wang, Xin, et al.
Publicado: (2014)

An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling
por: Hunt, Brian G., et al.
Publicado: (2023)

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
por: Feng, Liang, et al.
Publicado: (2016)

Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction
por: Wang, Ming-Hai, et al.
Publicado: (2013)

Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling
por: Chaudhuri, Amitabha
Publicado: (2014)

Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
por: Feng, Liang, et al.
Publicado: (2016)

RON tyrosine kinase mutations in brain metastases from lung cancer
por: Milan, Melissa, et al.
Publicado: (2018)

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells
por: Yao, Hang-Ping, et al.
Publicado: (2011)

The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma
por: Berning, Philipp, et al.
Publicado: (2020)

Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines
por: Zhou, Dong-Hui, et al.
Publicado: (2015)

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
por: Maitland, Michael L., et al.
Publicado: (2021)

Crystal Structure of the Sema-PSI Extracellular Domain of Human RON Receptor Tyrosine Kinase
por: Chao, Kinlin L., et al.
Publicado: (2012)

The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies
por: Cazes, Alex, et al.
Publicado: (2022)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

THE RON RECEPTOR TYROSINE KINASE POSITIVELY REGULATES ANGIOGENIC CHEMOKINE PRODUCTION IN PROSTATE CANCER CELLS
por: Thobe, Megan N., et al.
Publicado: (2009)

Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer
por: Batth, Izhar Singh, et al.
Publicado: (2021)

MicroRNA Expression Profiling of Lung Cancer with Differential Expression of the RON Receptor Tyrosine Kinase
por: Ou, Huilin, et al.
Publicado: (2021)

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
por: Weng, Tian-Hao, et al.
Publicado: (2020)

Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
por: Zou, Yi, et al.
Publicado: (2013)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells
por: Feres, K.J., et al.
Publicado: (2008)

Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues
por: Zhou, Donghui, et al.
Publicado: (2008)

Neuroprotective Role of the Ron Receptor Tyrosine Kinase Underlying Central Nervous System Inflammation in Health and Disease
por: Dey, Adwitia, et al.
Publicado: (2018)

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
por: Cunha, Stéphanie, et al.
Publicado: (2014)

Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
por: Ma, Qi, et al.
Publicado: (2010)

Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma
por: Keller, J, et al.
Publicado: (2013)

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
por: Kanteti, Rajani, et al.
Publicado: (2014)

A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells
por: Chakedis, Jeffery, et al.
Publicado: (2015)

OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase
por: Hao, Chengcheng, et al.
Publicado: (2019)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Conformation specific antagonistic high affinity antibodies to the RON receptor kinase for imaging and therapy
por: Yu Koh, Xin, et al.
Publicado: (2022)

Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates
por: Zwaagstra, John C., et al.
Publicado: (2019)

Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing
por: Krishnaswamy, Soundararajan, et al.
Publicado: (2017)

Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
por: Lambert, John M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fp5q91p8stkaaqvunurjng81ra